IO in EC: Rationales

CME

Rationales for Using Immunotherapy-Based Regimens in Advanced Endometrial Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: October 23, 2023

Expiration: October 22, 2024

Lauren Prescott
Lauren Prescott, MD, MPH
Ritu Salani
Ritu Salani, MD, MBA

Activity

Progress
1
Course Completed

Introduction

In this module, Lauren Prescott, MD, MPH, discusses the biologic rationales for using established and investigational immunotherapy-based regimens in the treatment of advanced endometrial cancer.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. One question will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a healthcare professional providing patient care, how many patients with endometrial cancer do you see in a typical month?

Presurvey

How would you describe the therapeutic and prognostic implications of the POLE-ultramutated molecular profile to a patient with advanced endometrial cancer?